Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Pater

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses|March 15, 2012
Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxisE J Bow, J L Pater, T J Louie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyJ L Pater, W S Lofters, B Zee, et al.
Breast Cancer Research and Treatment|January 12, 2011
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal womenT Cigler, H Richardson, M J Yaffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapyW S Lofters, J L Pater, B Zee, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
The economic impact of the transition from branded to generic oncology drugsW Y Cheung, E A Kornelsen, N Mittmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study GroupM Loeffler, O Brosteanu, D Hasenclever, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses|March 15, 2012
Reduction in clinical response to empiric antimicrobial therapy of febrile granulocytopenic patients receiving TMP/SMX infection prophylaxisE J Bow, J L Pater, T J Louie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyJ L Pater, W S Lofters, B Zee, et al.
Breast Cancer Research and Treatment|January 12, 2011
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal womenT Cigler, H Richardson, M J Yaffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapyW S Lofters, J L Pater, B Zee, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
The economic impact of the transition from branded to generic oncology drugsW Y Cheung, E A Kornelsen, N Mittmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study GroupM Loeffler, O Brosteanu, D Hasenclever, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Pageof 7